SCHEMBL14287397

SCHEMBL14287397

CC(C)NC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 14/20 0.75
LRRK2 Q5S007 6/20 0.75
PAK4 O96013 4/20 0.75
MAPK8 P45983 4/20 0.75
CLK4 Q9HAZ1 4/20 0.75
AURKA O14965 4/20 0.75
DAPK3 O43293 3/20 0.75
JAK2 O60674 3/20 0.75
RET P07949 3/20 0.75
LTK P29376 3/20 0.75
KDR P35968 3/20 0.75
MAP2K2 P36507 3/20 0.75
MAPK9 P45984 3/20 0.75
CLK2 P49760 3/20 0.75
RPS6KA3 P51812 3/20 0.75
JAK3 P52333 3/20 0.75
CDK5 Q00535 3/20 0.75
MAP2K1 Q02750 3/20 0.75
MST1R Q04912 3/20 0.75
MAP4K2 Q12851 3/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14287394 0.89 PTK2 (0.79) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14287396 0.89 PTK2 (0.78) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14287418 0.88 PTK2 (0.83) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14287398 0.87 PTK2 (0.85) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14287408 0.86 PTK2 (0.81) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14547851 0.86 LRRK2 (0.59) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14547936 0.86 PTK2 (0.83) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14287407 0.86 LRRK2 (0.82) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14287393 0.85 PTK2 (1.00) PTK2LRRK2PAK4MAPK8CLK4
SCHEMBL14547856 0.85 LRRK2 (0.58) PTK2LRRK2PAK4MAPK8CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
WO-2007042298-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042299-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004295-A1 NOVEL COMPOUNDS SYK, BTK, LCK PTK2 219/4885LRRK2 2483/4885PAK4 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.